Cargando…

Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics

PURPOSE: Imaging time-series data routinely collected in clinical trials are predominantly explored for covariates as covariates for survival analysis to support decision-making in oncology drug development. The key objective of this study was to assess if insights regarding two relapse resistance m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mistry, Hitesh B., Helmlinger, Gabriel, Al-Huniti, Nidal, Vishwanathan, Karthick, Yates, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6561994/ https://www.ncbi.nlm.nih.gov/pubmed/31020352 http://dx.doi.org/10.1007/s00280-019-03840-3

Ejemplares similares

Modeling Tumor Growth and Treatment Resistance Dynamics Characterizes Different Response to Gefitinib or Chemotherapy in Non‐Small Cell Lung Cancer
por: Nagase, Mario, et al.
Publicado: (2020)

Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach
por: Zhou, Diansong, et al.
Publicado: (2019)

Model based analysis of the heterogeneity in the tumour size dynamics differentiates vemurafenib, dabrafenib and trametinib in metastatic melanoma
por: Mistry, Hitesh B., et al.
Publicado: (2017)

Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model
por: Kosinsky, Yuri, et al.
Publicado: (2018)

On the relationship between tumour growth rate and survival in non-small cell lung cancer
por: Mistry, Hitesh B.
Publicado: (2017)

Predicting survival of pancreatic cancer patients treated with gemcitabine using longitudinal tumour size data
por: Wendling, Thierry, et al.
Publicado: (2016)

EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer
por: Selenz, Carolin, et al.
Publicado: (2022)

Longitudinal Tumor Size and Neutrophil‐to‐Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non‐Small Cell Lung Cancer Treated With Durvalumab
por: Gavrilov, Sergey, et al.
Publicado: (2020)

Impact of tumour size measurement inter-operator variability on model-based drug effect evaluation
por: Lombard, Aurélie, et al.
Publicado: (2020)

Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities
por: Al‐Huniti, Nidal, et al.
Publicado: (2020)

A simple model of a growing tumour
por: Orrell, David, et al.
Publicado: (2019)

Impact of Disease and Treatment Response in Drug–Drug Interaction Studies: Osimertinib and Simvastatin in Advanced Non‐Small Cell Lung Cancer
por: Vishwanathan, Karthick, et al.
Publicado: (2019)

EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer
por: Sonoda, Tomoaki, et al.
Publicado: (2018)

Radius additivity score: a novel combination index for tumour growth inhibition in fixed-dose xenograft studies
por: Melillo, Nicola, et al.
Publicado: (2023)

Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs
por: Gelardi, T, et al.
Publicado: (2008)

Population Exposure‐Response Modeling Supported Selection of Naloxegol Doses in Phase III Studies in Patients With Opioid‐Induced Constipation
por: Al‐Huniti, Nidal, et al.
Publicado: (2017)

Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia
por: Pu, Xia, et al.
Publicado: (2021)

Comparative benefit from small tumour size and adjuvant chemotherapy: clues for explaining breast cancer mortality decline
por: Demicheli, Romano, et al.
Publicado: (2014)

Resistance to Both Chemotherapy and EGFR-TKI in Small Cell Lung Cancer With EGFR 19-Del Mutation: A Case Report
por: Wang, Lingfei, et al.
Publicado: (2020)

Skipping a pillar does not make for strong foundations: Pharmacokinetic‐pharmacodynamic reasoning behind the shape of dose–response relationships in oncology
por: Yates, James W. T., et al.
Publicado: (2023)

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
por: Xia, Guo-Hao, et al.
Publicado: (2014)

Accelerated regrowth of non-small-cell lung tumours after induction chemotherapy
por: El Sharouni, S Y, et al.
Publicado: (2003)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

EGFR Exon 20 Insertion in Metastatic Non-Small-Cell Lung Cancer: Survival and Clinical Efficacy of EGFR Tyrosine-Kinase Inhibitor and Chemotherapy
por: Chelabi, Samy, et al.
Publicado: (2021)

Population pharmacokinetics modeling and exposure‐response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer
por: Nguyen, Jenny‐Hoa, et al.
Publicado: (2022)

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
por: Chung, Fu-Tsai, et al.
Publicado: (2015)

Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs
por: Bianco, R, et al.
Publicado: (2008)

Aloysia Citrodora Essential Oil Inhibits Melanoma Cell Growth and Migration by Targeting HB-EGF-EGFR Signaling
por: Salama, Yousef, et al.
Publicado: (2021)

Dual inhibition of EGFR and mTOR pathways in small cell lung cancer
por: Schmid, K, et al.
Publicado: (2010)

Inhibition of PLK1 Destabilizes EGFR and Sensitizes EGFR-Mutated Lung Cancer Cells to Small Molecule Inhibitor Osimertinib
por: Eggermont, Carolien, et al.
Publicado: (2023)

Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA
por: Tsuboi, Masahiro, et al.
Publicado: (2021)

Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
por: Kunimasa, Kei, et al.
Publicado: (2022)

Fluorescence ratio imaging of interstitial pH in solid tumours: effect of glucose on spatial and temporal gradients.
por: Dellian, M., et al.
Publicado: (1996)

Development, Verification, and Prediction of Osimertinib Drug–Drug Interactions Using PBPK Modeling Approach to Inform Drug Label
por: Pilla Reddy, Venkatesh, et al.
Publicado: (2018)

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
por: Russo, Alessandro, et al.
Publicado: (2015)

Dual inhibition of EGFR-VEGF: An effective approach to the treatment of advanced non-small cell lung cancer with EGFR mutation (Review)
por: Wang, Qian, et al.
Publicado: (2023)

Diagnostic accuracy of MRI to evaluate tumour response and residual tumour size after neoadjuvant chemotherapy in breast cancer patients
por: Bouzón, Alberto, et al.
Publicado: (2016)

Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status
por: Jian, Hong, et al.
Publicado: (2017)

Comparison of the outcome between immunotherapy alone or in combination with chemotherapy in EGFR-mutant non-small cell lung cancer
por: Shen, Chia-I, et al.
Publicado: (2021)

MET-8 Chemotherapy alone for brain metastases from small cell lung cancer -comparison with EGFR-TKI-
por: Iuchi, Toshihiko, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6mf1ollugsb4b2k79e7up6d2i4